Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4862865 | 0.85 | GAA (0.48) | ALDH1A1L3MBTL1MAOBSMN1; SMN2GAA | |
| SCHEMBL4750336 | 0.79 | GLS (0.50) | ALDH1A1MAOBGLS | |
| SCHEMBL30793979 | 0.79 | GLS (0.50) | ALDH1A1MAOBSMN1; SMN2GLS | |
| SCHEMBL4871009 | 0.75 | ALDH1A1 (0.41) | ALDH1A1L3MBTL1MAOBSMN1; SMN2HSD17B10 | |
| SCHEMBL4863424 | 0.74 | PDE10A (0.46) | ALDH1A1MAOBSMN1; SMN2 | |
| SCHEMBL8489619 | 0.72 | CA12 (0.47) | SMN1; SMN2 | |
| SCHEMBL2083743 | 0.71 | MAOB (0.48) | ALDH1A1MAOBSMN1; SMN2GAAHSD17B10 | |
| SCHEMBL2082949 | 0.71 | MAOB (0.48) | ALDH1A1MAOBSMN1; SMN2GAAHSD17B10 | |
| SCHEMBL3186901 | 0.70 | KMT2A (0.48) | ALDH1A1MAOBSMN1; SMN2 | |
| SCHEMBL3186877 | 0.70 | KMT2A (0.48) | ALDH1A1MAOBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080287376-A1 | Ketolide Derivatives as Antibacterial Agents | Salman, Mohammad (US) | 2008-11-20 | — | — | US | disclosed |
| EP-1794171-A2 | KETOLIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES, LTD. (IN) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006080954-A1 | KETOLIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287376-A1 | Ketolide Derivatives as Antibacterial Agents | MGAM, MGAM2, HEXA | ALDH1A1 3461/4885L3MBTL1 3188/4885TSHR 3491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.